References:
1. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory . April 2020:1-2. doi:10.1016/S2213-2600(20)30216-2.
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet . 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.
3. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R. MMWR - Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. CDC MMWR . 2020;69(15):458-464.
4. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias.Clin Infect Dis . March 2020:1-21. doi:10.1093/cid/ciaa247/5803302.
5. Nur E, Gaartman AE, Tuijn CFJ, Tang MW, Biemond BJ. Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID‐19). Am J Hematol . April 2020. doi:10.1002/ajh.25821.
6. Zaidi GZ, Rosentsveyg JA, Fomani KF, Louie JP, Koenig SJ. Reversal of Severe Multiorgan Failure Associated with Sickle Cell Crisis Using Plasma Exchange: A Case Series. J Intensive Care Med . 2019;35(2):140-148. doi:10.1177/0885066619874041.
7. Fortenberry JD, Nguyen T, Grunwell JR, et al. Therapeutic Plasma Exchange in Children with Thrombocytopenia-Associated Multiple Organ Failure. Critical Care Medicine . 2019;47(3):e173-e181. doi:10.1097/CCM.0000000000003559.
8. McCollom JW, Dublis SA, Hoogeboom J, Doyle A, Templin J. Catastrophic Multi-Organ Failure with Bone Marrow Necrosis in a Sickle Cell Beta Plus Thalassemia Patient. Blood . 2014;124(21):4942-4942. doi:10.1182/blood.V124.21.4942.4942.
9. Kim HC. Red cell exchange: special focus on sickle cell disease.Hematology . 2014;2014(1):450-456. doi:10.1182/asheducation-2014.1.450.
10. Banerjee S, Owen C, Chopra S. Sickle cell hepatopathy.Hepatology . 2001;33(5):1021-1028. doi:10.1053/jhep.2001.24114.
11. Allali S, de Montalembert M, Brousse V, et al. Hepatobiliary Complications in Children with Sickle Cell Disease: A Retrospective Review of Medical Records from 616 Patients. JCM . 2019;8(9):1481-1496. doi:10.3390/jcm8091481.
12. Menaker N, Halligan K, Shur N, Paige J, Hickling M. Acute Liver Failure During Deferasirox Chelation: A Toxicity Worth Considering.J Pediatr Hematol Oncol . 2017;39(3):217-222.
13. Ramaswami A, Rosen DJ, Chu J, Wistinghausen B, Arnon R. Fulminant Liver Failure in a Child With b-Thalassemia on Deferasirox: A Case Report. J Pediatr Hematol Oncol . 2017;39(3):235-237.
14. Shah R, Taborda C, Chawla S. Acute and chronic hepatobiliary manifestations of sickle cell disease: A review. WJGP . 2017;8(3):108-116. doi:10.4291/wjgp.v8.i3.108.
15. Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J. Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series. The Journal of the Pediatric Infectious Diseases Society . May 2020:1-25. doi:10.1093/jpids/piaa069/5848127.
16. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet . 2020;395(10239):1771-1778. doi:10.1016/S0140-6736(20)31103-X.
17. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA . June 2020:1-11. doi:10.1001/jama.2020.10369.
18. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation . 2020;382:1370–22. doi:10.1161/CIRCULATIONAHA.120.048360.
19. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ . 2020;105:m2094-m2097. doi:10.1136/bmj.m2094.
20. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood . April 2020:1-21. doi:10.1182/blood.2020006000.
21. Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis.Gastroenterology . March 2020. doi:10.1053/j.gastro.2020.03.065.
22. Ma J, Xia P, Zhou Y, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clinical Immunology . 2020;214. doi:10.1016/j.clim.2020.108408.
23. Keith P, Day M, Perkins L, Lou Moyer, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Critical Care . 2020;24(1):128-131. doi:10.1186/s13054-020-2836-4.